American Century Companies Inc. Acquires 157,731 Shares of Hologic, Inc. (NASDAQ:HOLX)

American Century Companies Inc. lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 14.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,274,067 shares of the medical equipment provider’s stock after purchasing an additional 157,731 shares during the period. American Century Companies Inc. owned 0.56% of Hologic worth $91,848,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of HOLX. General Partner Inc. acquired a new position in Hologic during the fourth quarter valued at approximately $26,000. Venturi Wealth Management LLC boosted its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the period. First Horizon Advisors Inc. grew its stake in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC lifted its position in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HOLX has been the topic of several research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Evercore ISI reduced their price objective on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research report on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Hologic currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

NASDAQ HOLX opened at $61.89 on Tuesday. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a market cap of $13.89 billion, a P/E ratio of 19.52, a PEG ratio of 2.14 and a beta of 0.97. The company’s 50-day simple moving average is $65.89 and its 200 day simple moving average is $73.81.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.